Danaher Corporation ($DHR) Stock Forecast: Up 5.8% Today

What is Danaher Corporation?

Danaher Corporation (DHR) is a global conglomerate with a focus on healthcare, environmental, and industrial markets. It operates through various segments including Life Sciences, Diagnostics, and Environmental & Applied Solutions.

Why is Danaher Corporation going up?

DHR stock is up 5.8% on Apr 22, 2025 18:37

• Danaher (DHR) reported strong Q1 earnings, surpassing both earnings and revenue estimates, which likely contributed to the bullish movement in the stock.
• Despite a 1% year-over-year sales decrease in the Life Sciences segment, the overall performance beat expectations, indicating resilience in other segments.
• Analysts were optimistic about DHR's Q1 earnings, particularly in the Biotechnology segment, which likely boosted investor confidence and drove the stock higher.
• The consistent outperformance of Danaher over the past decade, with an average annual return of 12.55%, has also likely attracted investors to the stock, further fueling its bullish movement.

DHR Price Chart

DHR Technical Analysis

DHR News

Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y

DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments.

https://www.zacks.com/stock/news/2453084/danaher-q1-earnings-beat-estimates-life-sciences-sales-down-yy

Danaher ( DHR ) Surpasses Q1 Earnings and Revenue Estimates

Danaher (DHR) delivered earnings and revenue surprises of 16.05% and 3.34%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2452411/danaher-dhr-surpasses-q1-earnings-and-revenue-estimates

Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?

DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.

https://www.zacks.com/stock/news/2451947/danaher-gears-up-to-post-q1-earnings-is-a-beat-in-store

$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today - Danaher ( NYSE:DHR )

Danaher DHR has outperformed the market over the past 10 years by 2.96% on an annualized basis producing an average annual return of 12.55%. Currently, Danaher has a market capitalization of $133.67 billion.

https://www.benzinga.com/insights/news/25/04/44879415/100-invested-in-danaher-10-years-ago-would-be-worth-this-much-today

Exploring Analyst Estimates for Danaher ( DHR ) Q1 Earnings, Beyond Revenue and EPS

Besides Wall Street's top -and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.

https://www.zacks.com/stock/news/2449756/exploring-analyst-estimates-for-danaher-dhr-q1-earnings-beyond-revenue-and-eps

Trending Today

Avalanche ($AVAX) Crypto Forecast: Up 5.4% Today

Cardano ($ADA) Crypto Forecast: Up 5.0% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.2% Today

Bonk ($BONK) Crypto Forecast: Down 5.4% Today

Litecoin ($LTC) Crypto Forecast: Up 6.5% Today

Monero ($XMR) Crypto Forecast: Down 5.4% Today

Wormhole ($W) Crypto Forecast: Up 5.2% Today

Sei ($SEI) Crypto Forecast: Up 6.7% Today

Worldcoin ($WLD) Crypto Forecast: Down 7.9% Today

Movement ($MOVE) Crypto Forecast: Down 17.7% Today

Danaher Corporation Price History

19.06.2024 - DHR Stock was down 5.2%

• Despite Danaher's strong performance over the past 10 years, today's bearish movement could be attributed to profit-taking by investors after a prolonged period of outperformance.
• The upcoming second-quarter earnings report may have heightened market expectations, leading to a sell-off as investors may be cautious about potential risks or uncertainties.
• Danaher opening labs to expedite diagnostic development could have raised concerns about increased expenses or potential disruptions in existing operations, impacting investor sentiment.
• The comparison with conglomerate peers like Honeywell International Inc. (HON) may have also influenced market participants to reevaluate their positions in Danaher, contributing to the bearish movement.

29.00.2025 - DHR Stock was down 8.0%

• Danaher (DHR) fell short of earnings projections for Q4, with unfavorable surprises in earnings and revenue, raising concerns about its performance.
• Manhattan Associates (MANH) provided weak FY25 guidance, which may have impacted market sentiment negatively and influenced related stocks like Danaher.
• Unusual bearish options activity on Danaher indicates that some investors have a pessimistic outlook on the stock, potentially contributing to its decline.
• The varied performance of U.S. stock futures, including some stocks experiencing declines, likely added to the downward pressure on Danaher's stock price today.

29.00.2025 - DHR Stock was down 9.9%

• Danaher's Q4 earnings missed estimates, with a negative surprise on both earnings and revenue, indicating potential challenges in the company's financial performance.
• The decline in the diagnostics segment impacted overall earnings performance, highlighting a specific area of weakness within the company.
• The unusual options activity showing a bearish stance on Danaher suggests that investors with significant capital are taking a pessimistic view on the stock, potentially contributing to the downward pressure on its price.
• Overall, the combination of earnings miss, segment lag, and bearish sentiment from investors likely led to the bearish movement in Danaher's stock today.

15.00.2025 - DHR Stock was down 0.7%

• Although Danaher has historically outperformed the market, the recent bearish movement could be due to investors capitalizing on gains following a period of growth.
• Market dynamics or industry-specific developments impacting companies in a similar vein as Danaher might be influencing the stock's downturn.
• Given the current market environment, investors could be reallocating their investments, possibly exploring other industries or asset classes, leading to a decrease in Danaher's share value.

23.06.2024 - DHR Stock was up 6.4%

• Danaher's second-quarter earnings beat expectations, leading to a surge in its stock price.
• Despite a decrease in core sales in the Biotechnology segment, the overall performance of the company was impressive.
• The positive earnings report and the company's ability to surpass analyst estimates contributed to the significant rise in Danaher's stock price.
• The increase in price target by analysts and the upbeat earnings results acted as catalysts for the bullish movement in Danaher's stock today.

23.06.2024 - DHR Stock was up 7.8%

• Danaher Corporation (DHR) saw a significant uptick in its stock price following the release of its second-quarter earnings.
• The company surpassed earnings per share (EPS) and revenue expectations for Q2 2024, demonstrating solid financial performance.
• Strong performance in Danaher's bioprocessing business and the medical testing segment contributed to the earnings beat.
• Investor confidence in Danaher's financial results and strategic positioning in key markets likely fueled the positive market sentiment.

23.06.2024 - DHR Stock was up 7.5%

• Danaher beat Q2 profit estimates, showcasing strength in its medical testing business, which likely boosted investor confidence in the company's performance.
• The company's Q2 earnings and revenues surpassed estimates, indicating solid financial health and potential growth prospects, which could have attracted more investors to the stock.
• Despite a decline in Q2 profit compared to the previous year, Danaher still managed to beat expectations, demonstrating resilience and effective cost management strategies in a challenging economic environment.
• The positive earnings report from Danaher amidst a mixed market sentiment, with some sectors lagging and specific companies facing revenue forecast challenges, could have contributed to the bullish movement in DHR stock as investors sought out stable and outperforming companies in the sector.

04.03.2025 - DHR Stock was down 6.1%

• Unusual bearish options activity observed for Danaher (DHR) indicates a significant number of investors are betting on a downward movement in the stock price.
• The bearish stance taken by investors could be due to concerns about the company's financial performance, industry outlook, or broader market conditions.
• This bearish movement may also be influenced by macroeconomic factors or specific company-related news that has impacted investor sentiment towards Danaher.

04.03.2025 - DHR Stock was down 7.4%

• Today's bearish movement in DHR stock is linked to concerns regarding the performance of its Life Sciences and Biotechnology units.
• Despite the positive performance in the clinical diagnostics business and the recent Abcam acquisition, challenges in certain segments appear to have impacted investor sentiment.
• Unusual options activity suggesting a bearish stance from investors with significant capital may have intensified the downward pressure on DHR stock.
• Investors are closely observing Danaher's efforts to address the issues in its underperforming units and leverage opportunities in its thriving businesses to restore market confidence and reverse the bearish trend.

22.03.2025 - DHR Stock was up 5.6%

• Danaher (DHR) surpassed both earnings and revenue projections for the first quarter of 2025, demonstrating robust financial results.
• The Biotechnology segment's strength is believed to have contributed significantly to the favorable earnings outcome, compensating for weaknesses in the Diagnostics and Life Sciences divisions.
• Market analysts had set high anticipations for Danaher's Q1 earnings, expecting an outperformance based on the company's historical performance and market positioning.
• Danaher's consistent outperformance over the past decade, boasting an average annual return of 12.55%, is indicative of the company's strong long-term growth strategy and market resilience.

22.03.2025 - DHR Stock was up 5.8%

• Danaher (DHR) reported strong Q1 earnings, surpassing both earnings and revenue estimates, which likely contributed to the bullish movement in the stock.
• Despite a 1% year-over-year sales decrease in the Life Sciences segment, the overall performance beat expectations, indicating resilience in other segments.
• Analysts were optimistic about DHR's Q1 earnings, particularly in the Biotechnology segment, which likely boosted investor confidence and drove the stock higher.
• The consistent outperformance of Danaher over the past decade, with an average annual return of 12.55%, has also likely attracted investors to the stock, further fueling its bullish movement.

10.03.2025 - DHR Stock was up 5.7%

• The bullish movement in DHR stock today can be attributed to:
• Positive analyst sentiment and upgrades, indicating growing confidence in the company's performance and potential.
• Strength in the clinical diagnostics business, driven by recent acquisitions like Abcam and shareholder-friendly policies, boosting investor optimism.
• Despite concerns in the Life Sciences and Biotechnology units, the overall positive outlook for the company's core businesses is overshadowing these challenges, leading to the bullish momentum in the stock.